Literature DB >> 2241286

Significance of low molecular weight C1q in systemic lupus erythematosus.

R Hoekzema1, A J Swaak, M C Brouwer, A van Rooijen, E J Nieuwenhuys, C E Hack.   

Abstract

The significance of high serum concentrations of low molecular weight C1q (LMW-C1q) in patients with systemic lupus erythematosus (SLE) was studied. Concentrations of LMW-C1q were increased in SLE, but not in rheumatoid arthritis or acute poststreptococcal glomerulonephritis. Concentrations of LMW-C1q in SLE serum samples correlated with titres of anti-dsDNA and were inversely related to concentrations of normal C1q and C3. Serial studies in six patients, who had rising anti-dsDNA titres and who developed a major exacerbation requiring admission to hospital, showed that LMW-C1q increased in parallel with anti-dsDNA, reaching peak values of more than 2000% of normal just before or at the time of clinical relapse and decreasing during convalescence. Most marked increases in LMW-C1q were noted in the three patients in whom C1q concentrations remained normal, whereas increases were less in the three patients who had strongly depressed concentrations of normal C1q. A study of C1q biosynthesis by macrophages cultured from patients with SLE and high serum concentrations of LMW-C1q did not show impaired secretion of normal C1q in favour of LMW-C1q, but indicated that serum concentrations of LMW-C1q may reflect the synthetic rate of C1q in vivo. The results show that increased serum concentrations of LMW-C1q may be helpful in diagnosing SLE and suggest that serial determination of LMW-C1q in serum may have predictive value in monitoring patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2241286      PMCID: PMC1004207          DOI: 10.1136/ard.49.9.698

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus.

Authors:  A J Swaak; L A Aarden; L W Statius van Eps; T E Feltkamp
Journal:  Arthritis Rheum       Date:  1979-03

2.  Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.

Authors:  A J Sliwinski; N J Zvaifler
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

3.  Effects of soluble aggregates of IgG on the binding, uptake and degradation of the C1q subcomponent of complement by adherent guinea pig peritoneal macrophages.

Authors:  R Veerhuis; L A Van Es; M R Daha
Journal:  Eur J Immunol       Date:  1985-09       Impact factor: 5.532

4.  Significance of persisting serologic abnormalities in SLE.

Authors:  R W Lightfoot; G R Hughes
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

5.  Anti-dsDNA and complement profiles in systemic lupus erythematosus.

Authors:  A J Swaak; J Groenwold; W Bronsveld; J Douma; T E Feltkamp
Journal:  Neth J Med       Date:  1981       Impact factor: 1.422

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Large-scale purification and cryopreservation of human monocytes.

Authors:  M De Boer; R Reijneke; R J Van de Griend; J A Loos; D Roos
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

8.  In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates.

Authors:  R Veerhuis; L A van Es; M R Daha
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

9.  SLE like syndrome and functional deficiency of C1q in members of a large family.

Authors:  A J Hannema; J C Kluin-Nelemans; C E Hack; A J Eerenberg-Belmer; C Mallée; H P van Helden
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

10.  Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.

Authors:  C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

View more
  4 in total

Review 1.  C1q nephropathy in the pediatric population: pathology and pathogenesis.

Authors:  Scott E Wenderfer; Rita D Swinford; Michael C Braun
Journal:  Pediatr Nephrol       Date:  2010-02-24       Impact factor: 3.714

2.  C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes.

Authors:  Deanna M Santer; Brian E Hall; Thaddeus C George; Stephanie Tangsombatvisit; Chih Long Liu; Peter D Arkwright; Keith B Elkon
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

3.  C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus.

Authors:  Rosanne A van Schaarenburg; César Magro-Checa; Jaap A Bakker; Y K Onno Teng; Ingeborg M Bajema; Tom W Huizinga; Gerda M Steup-Beekman; Leendert A Trouw
Journal:  Front Immunol       Date:  2016-12-27       Impact factor: 7.561

Review 4.  Complement Activation in Inflammatory Skin Diseases.

Authors:  Jenny Giang; Marc A J Seelen; Martijn B A van Doorn; Robert Rissmann; Errol P Prens; Jeffrey Damman
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.